These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31577867)

  • 21. Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
    Katzman MA; Therrien F; MacKenzie EM; Wang F; de Jong-Laird A; Boucher M
    J Affect Disord; 2022 Nov; 316():201-208. PubMed ID: 35970327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
    Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
    Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
    Krystal AD; Mittoux A; Meisels P; Baker RA
    Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
    Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
    J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
    McKeage K
    CNS Drugs; 2016 Feb; 30(2):91-9. PubMed ID: 26849053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
    Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
    Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Fava M; Wisniewski SR; Thase ME; Baker RA; Tran QV; Pikalov A; Yang H; Marcus RN; Berman RM
    J Clin Psychopharmacol; 2009 Aug; 29(4):362-7. PubMed ID: 19593176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.
    McIntyre RS; Therrien F; Ismail Z; Meehan SR; Miguelez M; Larsen KG; Chen D; MacKenzie EM; Thase ME
    J Psychiatr Res; 2023 Jun; 162():71-78. PubMed ID: 37099968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
    J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
    Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.